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Background: Hyaluronan is an extracellular matrix glycosaminoglycan involved in invasion, proliferation and
metastasis of various types of carcinomas. In many cancers, aberrant hyaluronan expression implicates disease
progression and metastatic potential. Melanoma is an aggressive skin cancer. The role of hyaluronan in melanoma
progression including benign nevi and lymph node metastases has not been investigated earlier, nor the details of
its synthesis and degradation.
Methods: The melanocytic and dysplastic nevi, in situ melanomas, superficially and deeply invasive melanomas and
their lymph node metastases were analysed immunohistochemically for the amount of hyaluronan, its cell surface
receptor CD44, hyaluronan synthases 1–3 and hyaluronidases 1–2.
Results: Hyaluronan content of tumoral cells in deeply invasive melanomas and metastatic lesions was clearly
reduced compared to superficial melanomas or benign lesions. Furthermore, hyaluronan content in the stromal
cells of benign nevi was higher than in the premalignant or malignant tumors. The immunopositivity of
hyaluronidase 2 was significantly increased in the premalignant and malignant lesions indicating its specific role in
the degradation of hyaluronan during tumor progression. Similarly, the expression of hyaluronan synthases 1–2 and
CD44 receptor was decreased in the metastases compared to the primary melanomas.
Conclusions: These findings suggest that the reciprocal relationship between the degrading and synthesizing
enzymes account for the alterations in hyaluronan content during the growth of melanoma. These results provide new
information about hyaluronan metabolism in benign, premalignant and malignant melanocytic tumors of the skin.
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Malignant melanoma is an aggressive skin cancer with
rapidly increasing incidence worldwide [1,2]. At the early
phase, the disease can often be cured surgically, but the
prognosis is worse in advanced stages resulting from its
therapy resistance [3]. Although exposure to UV radiation
is considered as the major risk factor for melanoma [4], a* Correspondence: hanna.siiskonen@uef.fi
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reproduction in any medium, provided the orlarge number of nevi and atypical dysplastic nevi are asso-
ciated with increased risk [5].
The dynamic extracellular matrix has been shown to
contribute to cancer progression. In the skin, an abun-
dant extracellular matrix molecule is hyaluronan (HA),
which is composed of repeating disaccharide units of
N-acetylglucosamine and glucuronic acid. This simple
sugar molecule has been shown to enhance tumor cell
invasion, proliferation and metastasis, and to promote drug
resistance leading to a poor clinical prognosis (reviewed
in [6]). In many malignancies of epithelial origin, i.e. car-
cinomas, the amount of hyaluronan differs from that of
the normal tissue depending on the cell type. Thus, inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(reviewed in [7]), the increased amount of hyaluronan cor-
relates directly with tumor grade and poor prognosis. On
the contrary, in squamous cell carcinomas (SCC) of the
skin [8], mouth [9], larynx [10] and lung [11], hyaluronan
content is decreased in high-grade tumors and, e.g., in oral
SCC is associated with poor prognosis [9]. Ultraviolet
radiation, the most important risk factor for melanoma,
has been shown to cause accumulation of hyaluronan
and development of hyperplasia, dysplasia and SCC in
mouse skin following long-term exposure, suggesting a
role for hyaluronan in the early phases of malignant
transformation in ultraviolet-exposed skin [12].
In a mouse model of melanoma, the amount of
hyaluronan has been shown to be increased during the
early stages of invasion and was localized at the inter-
face between tumor cells and their stroma [13]. In
vitro studies have shown that increased production of
hyaluronan correlates with increased motility of mel-
anoma cells [14] and prevention of hyaluronan synthesis
by 4-methylumbelliferone (4-MU) decreases melanoma
cell migration, adhesion [15,16] and invasion in 3D-
melanoma cultures [17]. Melanoma cells also secrete
several soluble factors like PDGF and IL-1β, which acti-
vate fibroblast hyaluronan synthesis and thus modulate
the composition of the tumor stroma more favourable
for cancer cell invasion and growth [18,19]. The role of
hyaluronan synthases (HAS) and hyaluronan-degrading
hyaluronidases (HYAL) has been investigated in many
adenocarcinomas [20-23], but not widely in cancers
with reduced hyaluronan expression.
In many epithelial cancers, hyaluronan content corre-
lates positively with CD44, the main hyaluronan receptor
[10,11,24]. Expression of CD44 is decreased in melano-
mas inversely correlating with increasing size, depth and
level of invasion, while uniform expression is found in
benign nevomelanocytic lesions [25]. Similarly, the levels
of hyaluronan and its receptor CD44 are reduced in
clinical stage I melanomas associating with poor patient
prognosis [24]. However, the role of hyaluronan or de-
tails of its synthesis and degradation in other stages of
the disease including benign nevi have not been investi-
gated earlier in human tissues. In this study, we ana-
lyzed the content of hyaluronan and expression of
enzymes involved in its metabolism in the human cuta-
neous melanocytic lesions including benign nevi, pre-




This retrospective study consists of 130 specimens taken
during the years 2000–2008 in Kuopio University Hospital.
The study was approved by the Ethics committee of theKuopio University Hospital and by The Finnish National
Supervisory Authority for Welfare and Health. The samples
consisted of 29 benign nevi (14 intradermal, 10 compound
and 5 junctional nevi), 28 dysplastic nevi, 18 in situ mela-
nomas, 17 superficial melanomas (invasion depth < 1 mm),
19 deep melanomas (invasion depth > 4 mm) and 19 lymph
node (LN) metastases. After biopsy, the tissue samples
were fixed in 10% buffered formaldehyde, embedded in
paraffin and sectioned 5 μm thick. For evaluation of stain-
ing coverage and intensity, the tissue sections were stained
for hyaluronan, hyaluronan receptor CD44, hyaluronan
synthases 1–3 (HAS1-3) and hyaluronan degrading hyal-
uronidases 1–2 (HYAL1-2) as described below.Hyaluronan staining
The sections were rehydrated in descending xylene-
ethanol series, and incubated first with 3% H2O2 for
5 min to block endogenous peroxidases, and then with
1% bovine serum albumin (BSA) in 0.1 M Na-phosphate
buffer, pH 7.0 (PB) for 30 min at 37°C to block unspecific
binding of the probe, followed by overnight incubation
at 4°C with 2 μg/ml biotinylated hyaluronan binding
complex (bHABC), isolated from bovine articular cartil-
age and containing the biotinylated complex of link pro-
tein and G1 domain of aggrecan [26]. After washes with
PB, the sections were incubated with avidin-biotin per-
oxidase (1:200, Vector Laboratories, Irvine, CA) for 1 h.
The color was developed with 0.05% 3,30-diaminobenzidine
(DAB, Sigma, St.Louis, MO) containing 0.03% H2O2. The
sections were counterstained with Mayer’s hematoxylin for
2 min, washed, dehydrated, and mounted in DePex (BDH
Laboratory Supplies, Poole, England). The specificity of
the staining was controlled by predigesting the sections
with Streptomyces hyaluronidase (100 TRU/ml in acetate
buffer, pH 5.0 for 3 h at 37°C; Seikagaku, Kogyo, Tokyo,
Japan) in the presence of protease inhibitors (Additional
file 1: Figure S1).CD44 staining
Specimens were rehydrated as described above. After
blocking the endogenous peroxidase activity in 1% H2O2
for 5 min and unspecific binding as described above, the
sections were incubated overnight at 4°C with the pri-
mary antibody Hermes3 (a kind gift from Dr. Sirpa
Jalkanen, University of Turku, Finland) diluted in 1:200
in 1% BSA-PB. The sections were sequentially incubated
with a biotinylated anti-mouse secondary antibody (1:150,
Vector Laboratories, Burlingame, CA, USA) for 1 h at
room temperature. Avidin-biotin peroxidase and DAB
treatments as well as the counterstaining with Mayer’s
hematoxylin were carried out as described above. Hermes
3 detects an epitope in the standard backbone of CD44
and therefore also all splice variants of CD44. Control
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mary antibody.
HAS and HYAL stainings
The deparaffinized sections were incubated in 10 mM
citrate buffer, pH 6.0 for 15 min in a pressure cooker at
120°C, washed with PB, and treated for 5 min with 1%
H2O2 to block endogenous peroxidase activity. There-
after the sections were incubated in 1% BSA, 0.05%
Tween-20 and 0.1% gelatine (Sigma G-2500, Sigma) in
PB for 30 min to block nonspecific binding. The sections
were incubated overnight at 4°C with polyclonal anti-
bodies diluted in 1% BSA for HASes (Santa Cruz Biotech-
nology, Santa Cruz, CA: sc-34021 for HAS1 in 1:100,
sc-34067 for HAS2 in 1:120 and sc-34204 for HAS3 in 1:80)
or with the primary antibodies for HYALs (HPA002112
from Atlas Antibodies, Stockholm, Sweden for HYAL1
in 1:100 and Ab68608 from Abcam, Cambridge, UK for
HYAL2 in 1:100) followed by 1 h incubation with
biotinylated anti-goat antibody (1:1000, Vector Labora-
tories) for HASes or with biotinylated anti-rabbit anti-
body (1:200, Vector Laboratories) for HYALs. Visualization
of the bound antibodies, counterstaining and mounting
in DePex were carried out as described above. Control
sections were stained similarly, but omitting the primary
antibody (Additional file 1: Figure S1). In addition, the
specificity of the HAS antibodies was tested with cor-
responding peptides as described in [12] (Additional
file 1: Figure S1).
Evaluation of stainings
The stained sections were evaluated for staining cover-
age and intensity separately in melanocytic cells and in
the stroma surrounding the lesion by two independent
observers (HS, MP). The area of the staining was esti-
mated with a five-level scoring system from 0 to 4. Score
0 = negative was given when less than 5% of the cells
were positive. Score 1 was given when 6-25% of the cells
were positive, score 2 when 26-50% of the cells were
positive, score 3 when 51-75% of the cells were positive
and score 4 when 76-100% of the cells were positive.
The intensity of the staining was estimated with a four-
level scale from 0 to 3 as negative (0), weak (1), moder-
ate (2) or strong (3) (Additional file 2: Figure S2).
Statistical analysis
IBM SPSS Statistics 20 (IBM Corporation, Armonk,
New York, USA) was used for the statistical analysis of
the data. The different histological groups were com-
pared with Mann–Whitney U-test for statistically signifi-
cant differences between the groups. A difference was
considered statistically significant when the p-value was
less than 0.05. Correlations between the groups were
tested with Spearman’s rho. A correlation coefficientstronger than 0.5 with a p-value less than 0.05 was con-
sidered significant.
Results
Hyaluronan content is reduced in the malignant
melanocytic lesions
Hyaluronan staining was mainly localized in the pericellular
matrix of the melanocytic cells, although intensive diffuse
intracellular staining was also observed in almost all sam-
ples (Figure 1). Compared to benign nevi, hyaluronan
appeared to be widely present also in dysplastic nevi and
melanomas, but its intensity and thus the content of
hyaluronan in the tissue became first increased in in situ
melanomas and then later clearly decreased in invasive
melanomas. The staining pattern of LN metastases was
similar to deep melanomas.
In all lesions studied most melanocytic cells were
hyaluronan positive (Figures 1 and 2). Interestingly, the
proportion of hyaluronan positive cells was highest in in
situ melanomas (76-100%) and the lowest in deep melano-
mas (51-75%) and lymph node (LN) metastases (51-75%).
The percentage of positive hyaluronan staining turned out
to be significantly reduced in deep melanomas compared
to benign nevi (p=0.001), in situ melanomas (p=0.000)
and also superficial melanomas (p=0.007). In benign nevi,
the intensity of hyaluronan staining in melanocytic cells
was moderate in average. Similar to the coverage, also the
intensity of hyaluronan staining in melanocytic cells was
highest in in situ melanomas (mainly moderate or strong)
and lowest in deep melanomas (mainly weak) (Figures 1
and 2), these changes being statistically significant com-
pared to benign nevi (p=0.048 and p=0.001, respectively).
Intensity of hyaluronan staining in superficial melano-
mas varied from weak to strong and was similar to
benign nevi.
Hyaluronan positive area covered most of the stromal
tissue (76-100% in average) in all groups without any
significant differences among the groups. The staining
intensity of the stromal tissue was strong in benign nevi,
whereas other lesions displayed moderate to strong stain-
ing with few samples with weak intensity. The reduction
of stromal hyaluronan staining intensity in the other lesion
types was statistically significant (p=0.003-0.000).
The staining of CD44 is reduced in tumor and stromal
cells of malignant melanocytic lesions
Immunostaining of the hyaluronan receptor CD44 showed
relatively similar staining pattern as hyaluronan in differ-
ent stages of melanoma. CD44 localized on the plasma
membrane of melanocytic cells, making often a reticular
pattern in the tissue (Figure 1). Like hyaluronan, CD44
was strongly expressed in all lesions studied (Figures 1
and 2), more than 76% of the melanocytic cells being
positively stained in all benign nevi, dysplastic nevi and
Figure 1 Hyaluronan, CD44 and hyaluronidase (HYAL) 1–2 stainings of benign (a-d) and dysplastic nevi (e-h), in situ melanomas (i-l),
superficial (<1 mm, in m-p) and deep melanomas (>4 mm, in q-t) and lymph node (LN) metastases (u-x). Red arrows in (i) indicate the
increased hyaluronan staining intensity of melanocytic cells and stroma of in situ melanoma, showing also intracellular staining of hyaluronan.
Red arrow in (q) points to reduced hyaluronan staining and in (r) to reduced CD44 staining, while in (t) the arrow indicates the increased HYAL2
staining in deep melanomas. Black arrows in (h, l, p) indicate the increased HYAL2 staining in the melanocytic cells of dysplastic nevus (h), in situ
melanoma (l) and superficial melanoma (p). White asterisk in (i) indicates strong hyaluronan staining in tumor cells in in situ melanoma, while in
(q) the white asterisk shows the reduced hyaluronan staining of tumor cells in deep melanoma. White dash lines in (i-p) delineate the border
between the tumor cells and the stroma in in situ melanomas (i-l) and encircle the invasive tumor cells in superficial melanomas (m-p). Scale bar
in (a) 100 μm.
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Figure 2 Intensity and coverage of hyaluronan (HA) and CD44 stainings in benign and dysplastic nevi, in situ melanomas, superficial
(<1 mm) and deep (>4 mm) melanomas and lymph node (LN) metastases. Statistical differences between the groups are indicated by
brackets. The statistical significance of the differences was tested with Mann–Whitney U-test. * p <0.05, ** p <0.01 and *** p <0.001.
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mas (Figure 2). About one fourth of deep melanomas
presented reduced staining coverage (51-75%) (Figure 2),
differing significantly from benign nevi (p=0.007). The
proportion of CD44-positive melanocytic cells was even
lower (in 67% of samples coverage less than 76%) in LN
metastases compared to deep melanomas (p=0.006).
The CD44 staining intensity in melanocytic cells was
mostly either moderate or strong in other lesions exceptLN metastases which showed weaker staining (Figures 1
and 2). CD44 staining intensity displayed similar pattern
of increased staining in premalignant lesions as hyaluronan,
being increased in dysplastic nevi and in situ melanomas
(p=0.013 and p=0.004, respectively) compared to benign
nevi. The moderate intensity of CD44 staining found in
superficial and deep melanomas was thus decreased
compared to strong staining in in situ melanomas
(p=0.002 and p=0.000, respectively). Similar to the coverage
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further decreased in LN metastases compared to deep
melanomas (p=0.007).
In stroma, the coverage of CD44 staining was high
(76-100% in average) in benign and dysplastic nevi, in
situ melanomas and superficial melanomas and was not
statistically different among these groups. Interestingly,
the stromal staining coverage was 26-50% in average in
deep melanomas, significantly decreased from the level
found in benign nevi (p=0.000), in situ melanomas
(p=0.000) and superficial melanomas (p=0.000). The
stromal coverage of CD44 was only 6-25% in average
in LN metastases, but it was not significantly different
than in deep melanomas. The intensity of stromal CD44
staining was strong in benign and dysplastic nevi, all
other lesions showing reduced staining intensity com-
pared to benign nevi (p=0.010-0.000). The intensity of
CD44 staining was mostly weak in LN metastases,
significantly reduced from the level in deep melano-
mas (p=0.020).
The expression of HYAL2 is increased in melanocytic
lesions
Especially the staining of HYAL2 was changed in dysplas-
tic nevi and melanomas compared to benign nevi, provid-
ing a logical explanation for the observed alterations in
hyaluronan staining, but also suggesting a connection to
the reduced staining of CD44 as previously reported [27].
Cells showing HYAL1 or HYAL2 positive immunostaining
were mainly melanocytic cells, while the majority of stro-
mal cells were negative (Figure 1). Hyaluronidase positive
staining was localized intracellularly, spreading diffusely
throughout the cytoplasm (Figures 1 and 3).
In all groups, the proportion of HYAL1-positive
melanocytic cells was high (76-100%), however, the stain-
ing intensity was mainly either weak or moderate with-
out any significant differences compared to benign nevi
(Figure 3). Interestingly, the intensity of HYAL1 in
melanocytic cells was significantly reduced in superficial
(p=0.008) and deep melanomas (p=0.029) and also in LN
metastases (p=0.005) compared to in situ melanomas.
The proportion of HYAL2 positive melanocytic cells
varied from 0-5% to 76-100% in benign nevi, and was
either weak or moderate when present, while in other
melanocytic lesions over 76% of cells were positive and
the staining intensity was higher, varying from weak to
moderate or even strong (Figures 1 and 3). Differences
between benign nevi and the other lesions studied in
the HYAL2 staining in melanocytic cells were statistically
significant (p=0.042-0.006 for coverage and p=0.009-0.000
for intensity). The HYAL2 staining in melanocytic cells
was similar in LN metastases as in melanomas.
HYAL2 immunostaining in the stromal cells was very
modest in all groups studied, just a few cells werepositively stained and the intensity of the positive stain-
ing when detected was weak (Figure 3). However, higher
proportion of stromal cells were HYAL2 positive (6-25%)
in deep melanomas (p=0.028), and the intensity of stromal
HYAL2 staining was higher in dysplastic nevi (p=0.006)
and in superficial (p=0.006) and deep melanomas (p=0.010)
compared to benign nevi. In the stroma, the intensity
of HYAL2 immunoreactivity correlated negatively with
hyaluronan staining intensity in superficial melanomas
(correlation coefficient −0.655, p=0.040).
The expression of Hyaluronan synthase 1 and 2 is
decreased in melanomas
Immunostaining with HAS1-3 specific antibodies showed
positive staining in all samples studied regardless of the
lesion type (Figures 4 and 5). However, the proportion
of positive cells in the melanocytic and stromal cells and
subcellular localization of the staining showed differences
among the HAS isoforms. While most melanocytic cells
showed positive immunostaining for HAS1 and HAS2,
less than half of them were positive for HAS3. In stromal
cells HAS1 appeared to be the prevalent isoform, while
HAS2 and HAS3 were less abundant (Figures 4 and 5).
Immunostaining for HAS1-3 proteins was detected homog-
enously in the cytoplasm and at the plasma membrane.
The proportion of HAS1 positive melanocytic cells
tended to be higher in dysplastic nevi and melanomas com-
pared to benign nevi, although the difference was statisti-
cally significant only for dysplastic nevi (p=0.021). In LN
metastases the proportion of HAS1 positive melanocytic
cells was lower (6-25% in average) than in deep melanomas
(26-50% in average, p=0.039). Despite the variation in
staining coverage, the staining intensity for HAS1 in
melanocytic cells showed no differences between the
lesion groups.
In benign nevi, in average 26-50% of the stromal cells
were HAS1 positive, while in dysplastic nevi the propor-
tion of HAS1 positive cells was lower (6-25% in average,
p=0.005). In situ melanomas and superficial melanomas
resembled benign nevi, while in deep melanomas the
proportion of HAS1 positive cells was lower (typically
less than 6%, p=0.000) and only occasional HAS1 positive
stromal cells were found in LN metastases (Figure 5).
The HAS1 staining intensity in stromal cells showed
similar trend as the coverage. The highest intensities were
found in benign nevi, scored mainly as moderate or strong,
followed by dysplastic nevi and in situ melanomas showing
weak to moderate staining, and superficial and deep mela-
nomas showing mainly weak or negative staining, respect-
ively (Figure 5). All these groups differed significantly from
benign nevi (p=0.020-0.000). The stromal HAS1 staining in
LN metastases was similar to deep melanomas.
Staining of the melanocytic cells for HAS2 showed simi-
lar trends as HAS1 (Figure 5). The proportion of the
Figure 3 Intensity and coverage of hyaluronidase (HYAL) 1–2 stainings in benign and dysplastic nevi, in situ melanomas, superficial
(<1 mm) and deep (>4 mm) melanomas and lymph node (LN) metastases. Statistical differences between the groups are indicated by
brackets. The statistical significance of the differences was tested with Mann–Whitney U-test. * p <0.05, ** p <0.01 and *** p <0.001.
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cantly higher in dysplastic nevi (mean 76-100%, p=0.000)
and in situ melanomas (mean 76-100%, p=0.000) com-
pared to benign nevi (mean 26-50%). In superficial and
deep melanomas, the proportion of HAS2 positive
melanocytic cells was significantly lower (mean 51-75%and 26-50%, respectively) than in in situ melanomas
(p=0.043 and p=0.007, respectively).
The HAS2 staining intensity of melanocytic cells was
weak in general and did not differ between the groups.
Only few stromal cells were positively stained for HAS2
in all groups. The staining intensity for HAS2 in the
Figure 4 Hyaluronan synthase (HAS) 1–3 expression in benign (a-c) and dysplastic (d-f) nevi, in situ melanomas (g-i), superficial (j-l)
and deep melanomas (m-o) and lymph node (LN) metastases (p-r). Black arrows in (g-h) and (j-k) point to tumor cells in in situ melanomas
(g-h) and superficial melanomas (j-k) stained positively for HAS1 (g, j) and HAS2 (h, k). White dash lines in (g-i) delineate the border between the
tumor cells and the stroma in in situ melanomas. Red arrow in (q) and in (r) point to stroma of LN metastases negative for HAS2 and HAS3,
respectively. Scale bar in (a) 100 μm.
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moderate in benign and dysplastic nevi and in situ
melanomas, and from weak to negative in superficial
(p=0.001) and deep melanomas (p=0.002) compared to
benign nevi. Interestingly, the stroma of LN metastases
was negative for HAS2.
HAS3 staining was the weakest of the three hyaluronan
synthases. In half of the specimens practically no stainingwas observed in melanocytic cells (Figure 5). The staining
intensity, when detected, was generally weak, and there
were no constant differences between the different lesions
in HAS3 staining coverage or intensity in melanocytic
cells. HAS3 positive stromal cells were detected more in
benign nevi (6-25% in one fifth of the samples, although
0-5% in general), while in other groups the proportion of
HAS3 positive stromal cells was very low (only 0-5%). The
Figure 5 Intensity and coverage of hyaluronan synthase (HAS) 1–3 stainings in benign and dysplastic nevi, in situ
melanomas, superficial (<1 mm) and deep (>4 mm) melanomas and lymph node (LN) metastases. Statistical differences between the
groups are indicated by brackets. The statistical significance of the differences was tested with Mann–Whitney U-test. * p <0.05, ** p <0.01 and
*** p <0.001.
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dysplastic nevi and deep melanomas compared to benign
nevi (p=0.009 and p=0.030, respectively). The intensity of
stromal HAS3 was mostly weak in benign nevi, and nega-
tive in other lesions (Figure 5, p=0.009-0.000). Interest-
ingly, also HAS3 staining was totally absent in the stroma
of LN metastases.
Discussion
There is a growing evidence that hyaluronan has an
important role in promoting tumor progression of epi-
thelial malignancies (reviewed in [6]). In the present
work we studied for the first time the expression pattern
of hyaluronan-metabolizing enzymes and the hyaluronan
content in different stages of cutaneous melanocytic
lesions. The current study indicates that hyaluronan con-
tent is increased in the melanocytic cells during the early
stages of melanoma (in situ melanoma phase), but isthereafter declined. The staining of CD44 was similar to
the pattern of hyaluronan staining. Our results suggest
that the reduction of hyaluronan in the invasive melan-
oma is due to increased expression of hyaluronidase 2
and decreased expression of hyaluronan synthases 1–3.
These results are in line with the findings of reduced
hyaluronan level in cutaneous stage I melanoma [24]. Thus,
the loss of hyaluronan receptor CD44 in melanocytic cells
accompanied the decreased hyaluronan content. As CD44
has multifaceted role in the hyaluronan metabolism acting
both in ligation of hyaluronan on the cell surface [28-30]
and in its endocytosis [31,32], the significance of its loss
for hyaluronan metabolism in melanoma is somewhat
difficult to deduce. The role of other players involved in
hyaluronan metabolism like synthases and hyaluroni-
dases have not been previously studied in melanoma
progression. Our data suggest that changes in the ex-
pression of both synthetic and degrading enzymes occur
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temporal and spatial distributions.
The amount of hyaluronan seems to be biphasic in
premalignant and malignant melanocytic lesions. First,
in dysplastic nevi the expression of HAS1 and HAS2 in
the melanocytic cells is increased, although at this stage
the amount of hyaluronan is not yet different from be-
nign lesions. Then in in situ melanomas, the proportion
of HAS2 positive melanocytic cells is higher than in be-
nign nevi, and at this state the hyaluronan content is
also increased in melanocytic cells. This may indicate
the accumulation of hyaluronan behind the intact base-
ment membrane before the invasive phase has been
achieved. Instead, in the deep melanomas the tumor
cells show markedly reduced amount of hyaluronan, which
is associated with the increased expression of HYAL2.
Similarly in the stromal compartment hyaluronan content
is significantly decreased in melanomas compared to
benign lesions, concurrent with increased activity of
HYAL2 and decreased expression of hyaluronan synthases.
Although melanoma originates form melanocytes and
not from the stratified epidermis as such, similar ten-
dency to increased hyaluronan staining in premalignant
or early malignant lesions and decreased staining in
more advanced tumors has been reported earlier in squa-
mous cell carcinomas of oral [9], laryngeal [10], esopha-
geal [33] and skin [8] epithelium, all originating from
stratified epithelium.
It is possible that the elevated hyaluronan content in
in situ melanomas promote the very early events of car-
cinogenesis by facilitating cell migration [14,34,35] and
proliferation [36,37], and by protecting cancer cells from
apoptosis [38]. These effects of hyaluronan involve sig-
naling through CD44 [39-41]. Hyaluronan, CD44 and
another hyaluronan receptor, receptor for hyaluronan
mediated motility (RHAMM) have been shown to form
signaling complexes with extracellular regulated kinase
1/2 (ERK1/2), leading to increased motility of breast
cancer cells [42]. ERK1/2 is a member of the central
RAS pathway activated in nearly all melanomas [43],
possibly linking hyaluronan and CD44 signaling with
the activation of this pathway early in melanoma. The
decreased hyaluronan content found in advanced melano-
mas may also be important for the tumor progression, as
the clearance of the extracellular water-attractive gel-like
hyaluronan may give more space for inflammatory cells like
mast cells [44], which produce a range of cancer-cell stimu-
lating cytokines and chemokines [45,46] and thus further
enhance the malignant phenotype of the transformed cells.
HYAL2 expression was significantly increased in all
premalignant and malignant melanocytic lesions com-
pared to the benign nevi. In the urothelial carcinoma
[47], prostate adenocarcinoma [48] and breast carcinoma
[49] HYAL1 has been considered the mostly expressedtumor-derived hyaluronidase. In our specimens, the
staining pattern of HYAL1 was not altered in the lesions
compared to benign nevi, but the intensity of HYAL1 in
melanocytic cells was decreased in superficial and deep
melanoma and lymph node metastases compared to in
situ melanomas. The presence of hyaluronidase in tumor
cells has been shown to increase angiogenesis in vivo [50].
Hyaluronan oligosaccharides produced by hyaluronidases
mediate the angiogenic effects [51,52] and may also acti-
vate matrix metalloproteinases enhancing the invasion
of the tumor [53]. Interestingly, in a mouse model of
prostate cancer, co-expression of a hyaluronidase (HYAL1)
and a hyaluronan synthase (HAS2) significantly increased
angiogenesis [22]. An upregulation of both HYAL2 and
HAS1-2 in dysplastic nevi and in situ melanomas was
also observed in the present study. In our specimens,
the hyaluronan binding probe used in the hyaluronan
stainings detects hyaluronan oligosaccharides larger than
10 sugars, thus possibly detecting some of the fragmented
hyaluronan. However, it is also possible that some smaller
(<HA10) oligosaccharides still exist in the tissue, if not
diluted away during sample processing.
Previously, the role of hyaluronan in metastases has not
been widely studied. High amount of stromal hyaluronan
in the primary tumor has been shown to associate with
metastasis in prostate [54] and thyroid [55] cancer, both
representing tumors from simple epithelium. In tumors
from stratified epithelium, irregular and locally reduced
staining of hyaluronan and CD44 in the primary tumor
associated with high frequency of metastasis in laryngeal
squamous cell carcinoma [10]. However, the staining
pattern of the metastases was not analyzed in these stud-
ies. In a scid mouse model of human adenocarcinomas,
lung metastases of colon carcinoma showed similar
hyaluronan staining pattern as the primary tumor, but
hyaluronan synthases were absent [56]. In our data, the
staining pattern of the lymph node metastases resem-
bled that of the primary tumor, but the amount of CD44
and HAS1 were further reduced in the metastases com-
pared to deep melanomas. These results suggest that
the decreased hyaluronan content in lymph node metas-
tases is explained by reductions in its synthesis and
binding at the cell surface.
Conclusions
Our data show for the first time the biphasic pattern
of hyaluronan metabolism in cutaneous melanocytic
tumors revealing an increased hyaluronan synthesis in
premalignant lesions followed by reduced hyaluronan
content in malignant melanoma as a consequence of
decreased HAS expression and increased amount of
degradative HYAL2. Further studies are needed to clarify
the prognostic power of HYAL2 upregulation and HAS1-3
downregulation in melanoma.
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Additional file 1: Figure S1. Control stainings showing the specificity
of the probe used for staining of hyaluronan (a-b) and antibodies used
to detect HAS1-3 (c-h) and HYAL1-2 (i-l) are shown in in situ melanomas
(a-b for HA and c-h for HAS1-3) and in superficial melanomas (invasion
<1 mm) (i-l for HYAL1-2). To check the specificity of hyaluronan staining
(a, white asterisk), the sections were pre-digested with 100 TRU/ml
Streptomyces hyaluronidase in the presence of protease inhibitors
removing hyaluronan from the sections (b, black asterisk). Red dash lines
in (a-b) delineate the border between the tumor cells and the stroma.
To confirm the specificity of the HAS stainings (c-h), the primary
antibodies (HAS1 in (c), HAS2 in (e) and HAS3 in (g), white arrows in (c)
and (e)) were preincubated with the corresponding peptides (peptide
block of HAS1 in (d), HAS2 in (f) and HAS3 in (h), black arrows in (d) and
(f)) used in the immunization. For HYAL stainings (HYAL1 in (i) and
HYAL2 in (k), red asterisks), the specificity was checked by omitting the
primary antibody (HYAL1 in (j) and HYAL2 in (l), red asterisks). Scale bar
in (l) 100 μm.
Additional file 2: Figure S2. Different intensity levels of HYAL2 staining
in deep melanomas (a-c) shown as an example of the scoring. The
intensity of the staining was estimated with a four-level scale as negative,
weak (a), moderate (b) or strong (c). Scale bar in (a) 100 μm.
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